Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2020

Nov 24, 2020

30610_dirs_2020-11-24_c1a9f5da-9a7c-4f49-8d0c-12260440adbd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-11-23

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-11-23 Common Stock M 5000 $12.21 Acquired 5000 Direct
2020-11-23 Common Stock M 10000 $19.15 Acquired 15000 Direct
2020-11-23 Common Stock S 1440 $99.31 Disposed 13560 Direct
2020-11-23 Common Stock S 6836 $100.12 Disposed 6724 Direct
2020-11-23 Common Stock S 6724 $101.21 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-11-23 Stock Option (Right to Buy) $12.21 M 5000 Disposed 2027-02-23 Common Stock (5000) Direct
2020-11-23 Stock Option (Right to Buy) $19.15 M 10000 Disposed 2026-08-10 Common Stock (10000) Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.70 to $99.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.72 to $100.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

F6: This option is fully vested and exercisable.